Smith & Nephew plunges as weaker US knees

Smith & Nephew PLC shares plunged 12% after reporting third-quarter revenue growth of 5.0%, missing consensus expectations of 6.1% due to weaker performance in US knee replacement surgeries and sports medicine. Analysts noted a 2.3% decline in US knee revenues, suggesting significant market share loss despite reiterated guidance. The market is now focused on the company's December capital markets day for insights into its longer-term strategy.

Analysis

Smith & Nephew PLC (LSE:SN) shares experienced a significant 12% decline following its third-quarter earnings report, making it the worst performer on the FTSE 100. The company reported revenue growth of 5.0%, falling short of the consensus expectation of 6.1%, primarily due to a weaker performance in US knee replacement surgeries and softer sports medicine sales. This underperformance in orthopaedics was a key driver of the revenue miss.

The 2.3% decline in US knee revenues specifically indicates a meaningful loss of market share for Smith & Nephew during Q3, a point highlighted by Panmure Liberum analysts who attributed this partly to portfolio rationalization efforts. Despite management reiterating its full-year guidance, UBS analysts anticipate this will still disappoint against prior market expectations given the extent of the revenue miss.

Both analyst firms emphasize the critical importance of the upcoming December capital markets day. Investors are now keenly focused on this event for the company's detailed longer-term strategy, which is expected to outline how Smith & Nephew plans to address its market share challenges and reignite growth. The current share weakness reflects the market's reaction to the lack of materially new positive information in the recent statement.

Key Decisions for Investors

• Investors should closely monitor Smith & Nephew's December capital markets day for a clear long-term strategy addressing market share erosion in US orthopaedics and sports medicine.
• Re-evaluate the sustainability of the company's reiterated guidance given the significant Q3 revenue miss and analyst expectations for disappointment, which may lead to future downward revisions.
• Assess the competitive dynamics within the US knee replacement market, as the 2.3% revenue decline indicates meaningful market share loss for Smith & Nephew.
• Consider the implications of portfolio rationalization on future growth and profitability, and how management plans to regain momentum in key segments.